^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pomalidomide

    i
    Other names: CC 4047, CDC 394, CC-4047 , CDC-394, CC4047, CDC394
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor
    Related drugs:
    1d
    KarMMa-3: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=386, Completed, Celgene | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Apr 2026 | Trial primary completion date: Apr 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Abecma (idecabtagene vicleucel)
    5d
    Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients. (PubMed, J Transl Med)
    This study provides a new strategy for enhancing the activity of DEXs derived from patients with MM, with the potential to develop DEXs as an antitumor vaccine for MM.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD80 (CD80 Molecule) • CD81 (CD81 Molecule) • CD86 (CD86 Molecule)
    |
    pomalidomide
    6d
    Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Columbia University | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • pomalidomide • bendamustine • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets)
    7d
    64007957MMY2022: A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination withnPomalidomide Administered in Alternative Fashion in Participants with RRMM, whonReceived 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy (2025-522114-23-00)
    P1/2, N=35, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    lenalidomide • pomalidomide • Tecvayli (teclistamab-cqyv)
    8d
    Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. (PubMed, Br J Haematol)
    Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • dexamethasone • pomalidomide
    12d
    DREAMM8: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=302, Active, not recruiting, GlaxoSmithKline | Trial completion date: Oct 2029 --> Jun 2029
    Trial completion date
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    12d
    DREAMM 8: All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=21, Active, not recruiting, GlaxoSmithKline | Trial completion date: Nov 2029 --> Jun 2029
    Trial completion date
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    13d
    A fibroblast activation protein degrader enhances cisplatin sensitivity in non‑small cell lung cancer. (PubMed, Oncol Rep)
    In the present study, a fibroblast activation protein (FAP) degrader (Pomalidomide‑PEG2‑FAP2286: FAP‑D) was utilized to enhance cisplatin sensitivity in NSCLC. In conclusion, the study demonstrated that FAP‑D can enhance the cisplatin sensitivity of H1299 cells and NSCLC tumors. The present findings shed new light into promising treatment strategies and demonstrated the potential clinical utility of cisplatin + FAP‑D for NSCLC treatment.
    Journal
    |
    CASP3 (Caspase 3) • DPP4 (Dipeptidyl Peptidase 4)
    |
    cisplatin • pomalidomide • lutetium Lu 177 rofapitide tetraxetan (AAA614)
    15d
    GEM-BELACOMBOS: Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, PETHEMA Foundation
    New trial
    |
    B2M (Beta-2-microglobulin)
    |
    bortezomib • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    15d
    Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pomalidomide
    16d
    Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. (PubMed, Ann Med Surg (Lond))
    When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
    Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • pomalidomide • forimtamig (RG6234)
    16d
    KTX-MMSET-001: A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=165, Recruiting, K36 Therapeutics, Inc. | N=125 --> 165
    Enrollment change
    |
    carfilzomib • dexamethasone • pomalidomide • mezigdomide (CC-92480) • gintemetostat (KTX-1001)